在接受预防性CGRP向治疗的患者中增加感染风险 - - 一个元分析和临床效果评估
Marcin Straburzyński1, Daria Kopyt2, Karol Marschollek3
1Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury in Olsztyn, Warszawska 30, Olsztyn, 10-082, Poland. marcin.straburzynski@uwm.edu.pl.
素基因相关 (CGRP) 途径疗法可能会略微增加感染风险,特别是eptinezumab和galcanezumab. 然而,大多数偏头痛患者的整体风险仍然很低,因为伤害所需的数字很高.
科学领域:
- 免疫学和神经学 免疫学和神经学
- 对于CGRP路径抑制剂的药理学
背景情况:
- 素基因相关 (CGRP) 途径向疗法在临床使用中显示出有效性和安全性.
- 新出现的报道表明,CGRP参与免疫反应和感染风险增加之间存在潜在联系.
研究的目的:
- 系统地评估CGRP向疗法是否与感染风险增加有关.
- 分析在临床实践中使用的各种CGRP对抗剂中传染性不良事件的发生率.
主要方法:
- 进行了37个随机的安慰剂对照试验的系统审查和网络元分析.
- 包括22518名接受CGRP抗体治疗的患者的数据 (埃伦纽马布,弗雷曼纽马布,加尔卡内祖马布,埃普丁纽马布,阿托杰潘特,里梅杰潘特).
- 评估了感染性不良事件和严重不良事件的相对风险和损害所需的数量.
主要成果:
- 预防性CGRP向疗法显示感染风险略有增加 (RR 1.08).
- 加尔坎祖马布和eptinezumab单独与特定剂量的感染风险增加有关.
- 弗雷曼祖马布的严重传染性不良事件最少,而埃伦祖马布的发病率最高.
结论:
- 预防性CGRP通路抗剂,特别是eptinezumab和galcanezumab,可能会略微增加感染风险.
- 对于大多数偏头痛患者来说,临床影响可能是最小的,因为伤害所需的数量很高,效果大小很小.
- 免疫功能低下的个体或在公共卫生层面上,感染风险增加可能更明显.
更多相关视频
08:39Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
相关概念视频
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
